CoChat

Pharmacologic inhibition of lipogenesis for the treatment of NAFLD

Open access
Esler, William P., Cohen, David E. · 2024 · Journal of Hepatology
Cited by 111

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Summary The hepatic accumulation of excess triglycerides is a seminal event in the initiation and progression of non-alcoholic fatty liver disease. Hepatic steatosis occurs when the hepatic accrual of fatty acids by uptake from the plasma and by de novo lipogenesis (DNL) is no longer balanced by rates of fatty acid oxidation and by secretion as VLDL triglycerides. Accumulating data indicate that increased rates of DNL are central to the development of hepatic steatosis in NAFLD. Whereas the main drivers in NAFLD are transcriptional, owing to both hyperinsulinemia and hyperglycemia, the effectors of DNL are a series of well characterized enzymes. Several have proven amenable to pharmacologic inhibition or oligonucleotide-mediated knock down, with lead compounds that have been advanced to phase 2 clinical trials. These have largely proven effective. In human subjects with NAFLD, percent reductions in liver fat have closely mirror percent inhibition of DNL, thereby affirming the critical contributions of DNL to NAFLD pathogenesis. The safety profiles of these compounds have so far remained encouraging. It is anticipated that inhibitors of DNL, when administered alone or in combination with other therapeutic agents, will become important agents in the management of human NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.10.042

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 111

Metadata

Authors
Esler, W. P., & Cohen, D. E.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2024-02
Volume
80
Issue
2
Pages
362-377
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4388694639
Cited by
111
References
29
FWCI
18.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. https://app.cochat.ai/papers/10.1016/j.jhep.2023.10.042
The paper
Esler, W. P., & Cohen, D. E. (2024). Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2023.10.042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.